PURPOSE: To report 5-year clinical outcomes of 3 prospective trials of image-guided proton therapy for prostate cancer. METHODS AND MATERIALS: A total of 211 prostate cancer patients (89 low-risk, 82 intermediate-risk, and 40 high-risk) were treated in institutional review board-approved trials of 78 cobalt gray equivalent (CGE) in 39 fractions for low-risk disease, 78 to 82 CGE for intermediate-risk disease, and 78 CGE with concomitant docetaxel therapy followed by androgen deprivation therapy for high-risk disease. Toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Median follow-up was 5.2 years. RESULTS: Five-year rates of biochemical and clinical freedom from disease progression were 99%, 99%, and 76% in low-, intermediate-, and high-risk patients, respectively. Actuarial 5-year rates of late CTCAE, version 3.0 (or version 4.0) grade 3 gastrointestinal and urologic toxicity were 1.0% (0.5%) and 5.4% (1.0%), respectively. Median pretreatment scores and International Prostate Symptom Scores at >4 years posttreatment were 8 and 7, 6 and 6, and 9 and 8, respectively, among the low-, intermediate-, and high-risk patients. There were no significant changes between median pretreatment summary scores and Expanded Prostate Cancer Index Composite scores at >4 years for bowel, urinary irritative and/or obstructive, and urinary continence. CONCLUSIONS: Five-year clinical outcomes with image-guided proton therapy included extremely high efficacy, minimal physician-assessed toxicity, and excellent patient-reported outcomes. Further follow-up and a larger patient experience are necessary to confirm these favorable outcomes.
PURPOSE: To report 5-year clinical outcomes of 3 prospective trials of image-guided proton therapy for prostate cancer. METHODS AND MATERIALS: A total of 211 prostate cancerpatients (89 low-risk, 82 intermediate-risk, and 40 high-risk) were treated in institutional review board-approved trials of 78 cobalt gray equivalent (CGE) in 39 fractions for low-risk disease, 78 to 82 CGE for intermediate-risk disease, and 78 CGE with concomitant docetaxel therapy followed by androgen deprivation therapy for high-risk disease. Toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Median follow-up was 5.2 years. RESULTS: Five-year rates of biochemical and clinical freedom from disease progression were 99%, 99%, and 76% in low-, intermediate-, and high-risk patients, respectively. Actuarial 5-year rates of late CTCAE, version 3.0 (or version 4.0) grade 3 gastrointestinal and urologic toxicity were 1.0% (0.5%) and 5.4% (1.0%), respectively. Median pretreatment scores and International Prostate Symptom Scores at >4 years posttreatment were 8 and 7, 6 and 6, and 9 and 8, respectively, among the low-, intermediate-, and high-risk patients. There were no significant changes between median pretreatment summary scores and Expanded Prostate Cancer Index Composite scores at >4 years for bowel, urinary irritative and/or obstructive, and urinary continence. CONCLUSIONS: Five-year clinical outcomes with image-guided proton therapy included extremely high efficacy, minimal physician-assessed toxicity, and excellent patient-reported outcomes. Further follow-up and a larger patient experience are necessary to confirm these favorable outcomes.
Authors: Willy Baccaglini; Icaro T de Carvalho; Felipe P A Glina; Cristiano Linck Pazeto; André Marantes; Matheus Nascimento; Artur Farias; Lucas C Mendez; Alessandro Tafuri; Sidney Glina Journal: Clin Transl Oncol Date: 2022-03-04 Impact factor: 3.405
Authors: Stefan Höcht; Daniel M Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Tobias Hölscher; Thomas Martin; Felix Sedlmayer; Frederik Wenz; Daniel Zips; Thomas Wiegel Journal: Strahlenther Onkol Date: 2016-09-14 Impact factor: 3.621
Authors: William M Mendenhall; Gabriella Glassman; Christopher G Morris; Joseph A Costa; Christopher R Williams; Stephanie E Harris; Stephen E Mandia; Bradford S Hoppe; Randal H Henderson; Curtis M Bryant; R Charles Nichols; Nancy P Mendenhall Journal: Int J Part Ther Date: 2016-08-29
Authors: Jason M Slater; Jerry D Slater; Joseph I Kang; Ivan C Namihas; B Rodney Jabola; Kelcie Brown; Roger Grove; Cherie Watt; David A Bush Journal: Int J Part Ther Date: 2019-08-06
Authors: Thomas J Pugh; Seungtaek Choi; Graciela M Nogueras-Gonzalaez; Quyhn Nhu Nguyen; Usama Mahmood; Steven J Frank; Benson Mathai; X Ron Zhu; Narayan Sahoo; Michael Gillin; Deborah A Kuban; Karen E Hoffman; Sean E McGuire; Andrew K Lee Journal: Int J Part Ther Date: 2016-08-29